Anti-Aging Firm Unity Stumbles At First Major Hurdle
Hit By Lead Drug Failure In OA
Unity is set to drop its lead product based on its senescent cell science as it fails in a Phase II study in osteoarthritis of the knee. Focus switches to ophthalmic product.
